



REGULATED INFORMATION

**PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF
2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS
(THE “TRANSPARENCY LAW”)**

GHENT, Belgium, 27 August 2013 – **Ablynx [Euronext Brussels: ABLX]** today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from Gimv NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV.

The above shareholders notified that they have dropped below the 10% threshold and now hold 4,831,860 Ablynx shares.

Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life Sciences 2004 NV. Gimv NV (2,033,399 voting rights), Adviesbeheer Gimv Life Sciences NV (0 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV (360,973 voting rights) and Biotech Fonds Vlaanderen NV (2,437,488 voting rights) are acting in mutual agreement. The Flemish Region in Belgium is the ultimate shareholder of Biotech Fonds Vlaanderen NV.

Full versions of all transparency notifications are available on the website of Ablynx, under the section [Investors](#).

About Ablynx

[Ablynx](#) is a biopharmaceutical company engaged in the discovery and development of [Nanobodies®](#), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately [25 programmes in the pipeline](#) and six Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
 [@AblynxABLX](https://twitter.com/AblynxABLX)

Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville

t: +44 207 920 2345

e: ablynx@consilium-comms.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.